Table 3

Hematologic and serologic parameters Day -14 to end of treatment (EOT)

Patient #

White blood cells

(× 10⁹/l)

RR 3.9-10.7

Absolute lymphocytes

(× 10⁹/l)

RR 0.9-4.3

Absolute neutrophils

(× 10⁹/l)

RR 2.0-7.2

Day

-14

Day 1

Day 14 (± 1)

EOT

Day

-14

Day 1

Day 14 (± 1)

EOT

Day

-14

Day 1

Day 14 (± 1)

EOT

2

11.2

6.0

8.3

3.8

1.7

1.6

1.7

2.0

8.9

4.1

6.4

1.6^L1

8

6.3

15.1

12.4

8.1

0.8^L2

0.9

1.3

1.0

5.0

13.7

10.6

7.0

3

5.7

11.1

8.1

4.7

0.9

0.7^L2

0.5^L2

0.2^L3

4.4

10.1

7.4

4.3

5

2.8^L2

15.6

N/A

N/A

1.0

3.4

N/A

N/A

1.6^L1

10.6

N/A

N/A

13

14.7

5.6

8.5

7.6

1.5

0.7^L2

0.5^L3

0.7^L2

13.1

4.7

7.8

6.5

14

15.5^a

15.2

8.3^b

7.1

0.9^a

1.8

0.8^{L1, b}

0.8^L1

13.7^a

12.9

7.0^b

5.7

CD4⁺ (cells/μl) [%]

RR 404-1612 [33-58]

Complement C3 (g/l)

RR 0.9-1.8

Anti-dsDNA (IU/ml)

< 30.0, negative; 30-75, borderline; > 75, positive

Patient #

Day 1

Day 28 (± 2)

EOT

Day 1

Day 14 (± 1)

EOT

Day

-14

Day 1

Day 14 (± 1)

EOT

2

489 [25.8^L]

1731 [34.1]

980 [44.6]

0.686^L

0.904

0.721^L

917.2

375.7

168.1

463.9

8

277^L2 [23.5^L]^c

273^L2 [29.7^L]

195^L3 [24.0^L]

0.915

1.150

1.070

325.5

306.1

97.6

20.1

3

N/A

56^L3 [13.7^L]

45^L4 [21.4^L]

0.533^L

0.800^L

0.906

155.3

77.6

37.5

< 12.3

5

529 [22.1^L]

809 [30.1^L]

603 [46.8]

1.030

1.630

1.700

56.7

43.0

34.3

12.6

13

240^L2 [38.7]

95^L3 [23.8^L]

163^L3 [19.3^L]

0.462^L

0.717

0.909

87.5

26.0

13.0

12.7

14

135^L3 [19.1^L]

N/A

158^L3 [19.9^L]

0.434^L

0.541^b

0.609^L

349.6

88.1

28.8^b

20.1

Patients #2 and #8 randomized to placebo; Patients #3, #5, #13 and #14 randomized to atacicept 150 mg subcutaneously twice weekly (4 weeks), then 150 mg weekly (48 weeks). N/A, not available; RR, reference range. Values > ULN indicated in italics; ^LValues < LLN, with Grade (1 to 4), where applicable. ^aMeasured Day -10; ^bMeasured Day 18; ^cMeasured Day 4.

Ginzler et al. Arthritis Research & Therapy 2012 14:R33   doi:10.1186/ar3738